Skip to content

Perfusion Extracorporeal Technology

Active Private limited companyfounded 2022active for 4 yearsRue des Haipes, Sauv. 8, 5030 GemblouxKBO/BCE: BE 0784.827.493

Lifetime

4 annual accounts with figures on one time axis
peak of €13,859 in 2022
-€3,940▼ €10,913
lowest -€6,541 in 2025
-€6,541▼ €8,820
peak of €15,277 in 2024
€8,736▼ 42.8%
€24,043▲ 67.9%
Board1 name since 2022
1 director
Documentsfilings and deeds
11-06-202650 days before the deadline
2025micro format
Gross margin from €6,973 to -€3,940Loss of €6,541Equity from €15,277 to €8,736Debts from €14,322 to €24,043Investments €4,299

Key points

from the 2025 annual accounts

Debts

€24,043 73% of the balance sheet
Suppliers 50%Taxes and wages 33%Other 17%

Investments

€4,454 2.9 times depreciation
2022202320242025

Green is investment, beige is depreciation.

Liquidity

1.16 was 1.91 in 2024

Short-term debts rose from €14,322 to €24,043.

Filings

4 annual accounts 2 late
AprilJune31 JulyOctober2022202320242025

The 2022 accounts came in latest, 29 days after the end of the period.

Position in the sector

-€6,541

Lower net result than 85% of companies in office administrative support. The sector median is €15,226, over 10,284 companies.

Turnover not published in the micro format

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 1,207 companies had the same profile as Perfusion Extracorporeal Technology has now. Each dot stands for 4 companies, two years later.

90.1%
were still trading
4.8%
stopped another way
4.6%
went bankrupt
  • Micro
  • 2 to 5 years old
  • solvency 10 to 30%
  • a loss of 10% of the balance sheet or more

Another 0.6% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 1,207 companies, not a prediction for Perfusion Extracorporeal Technology. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 08-04-2022
  • 100 sharesdeed of 19-04-2022
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0784827493
Incorporation Founding capital of €2,000, 100 shares · Founded by · appointed as director · published on 19-04-2022 · Gazette deed
First establishment PEx Tech, Rue des Haipes, Sauv. 8, Gembloux
All 8 events

Comparable companies

same main activity, similar in size and age
Company
Perfusion Extracorporeal Technology Gembloux €32,779 -€3,940 26.7% -
AM BC INVEST Profondeville €36,543 -€6,363 -6.2% -
WILO-VET Perwez €32,858 -€760 -1.0% -
C2IT Antwerp €30,570 -€8,905 64.1% -
SIGRID COX Herk-de-Stad €32,770 €1,066 -69.0% -
SELIGO Overijse €36,105 -€53,327 5.3% -
MAZ2C Waterloo €34,183 -€27,707 -312.5% -

These companies have the same main activity as Perfusion Extracorporeal Technology: other business support services (NACE 82990). They are comparable in size and age: total assets between €30,600 and €36,500, founded in 2022.

Official details

Source: KBO
Status
Active since 14-04-2022Normal situation
Activity
Other business support servicesNACE 82990and 1 other
Establishment unit
2.330.746.2865030 Gembloux, since 14-04-2022
Financial year end
31 December
Peppol
Reachable since 29-12-2025
Company details

Annual accounts 2025

€32,779▲ 10.7%
Filing
Filed on 11-06-2026, 50 days before the end of the filing period
Financials

Insights on Perfusion Extracorporeal Technology

Perfusion Extracorporeal Technology files the micro format. That format states no turnover. The gross margin fell from €13,859 in 2022 to -€3,940 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about Perfusion Extracorporeal Technology

What is the company number of Perfusion Extracorporeal Technology?
The company number of Perfusion Extracorporeal Technology is 0784.827.493. The VAT number is the same number with BE in front: BE 0784.827.493.
Where is Perfusion Extracorporeal Technology based?
The registered office is at Rue des Haipes, Sauv. 8, 5030 Gembloux.Company details
What does Perfusion Extracorporeal Technology do?
According to the KBO register, the main activity is other business support services (NACE 82990).
What is the legal form of Perfusion Extracorporeal Technology?
Perfusion Extracorporeal Technology is a private limited company (BV).
When was Perfusion Extracorporeal Technology founded?
Perfusion Extracorporeal Technology was founded on 14-04-2022.
Is Perfusion Extracorporeal Technology still active?
Yes, Perfusion Extracorporeal Technology is an active enterprise in the KBO register.
What is the turnover of Perfusion Extracorporeal Technology?
The annual accounts for financial year 2025 state no turnover. The micro format does not require it.Financials
Is Perfusion Extracorporeal Technology profitable?
In financial year 2025, Perfusion Extracorporeal Technology made a loss of €6,541.
Where can I find the annual accounts of Perfusion Extracorporeal Technology?
Perfusion Extracorporeal Technology filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Perfusion Extracorporeal Technology due?
Perfusion Extracorporeal Technology must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.